NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics Forum

  NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics
  Forum

Canaccord Genuity Medical Technology & Diagnostics Forum 2013

Business Wire

WALTHAM, Mass. -- November 7, 2013

NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device
company focused on the treatment and management of the neurological
complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D.,
President and Chief Executive Officer, is scheduled to speak at the Canaccord
Genuity Medical Technology & Diagnostics Forum at The Westin Grand Central,
New York, NY on November 14, 2013. Dr. Gozani intends to provide an update on
the Company’s business activities with particular emphasis on its SENSUS^™
pain management system for relief of chronic intractable pain, including pain
associated with diabetic neuropathy.

NeuroMetrix's presentation is scheduled for Thursday, November 14, 2013 at
8:00 am (Eastern Daylight Time). A live audio webcast will be available on the
investor relations section of the corporate website - www.neurometrix.com.
This webcast will be archived after the live event.

About NeuroMetrix

NeuroMetrixis a medical device company that develops and markets home use and
point-of-care devices for the treatment and management of chronic pain,
peripheral neuropathies, and associated neurological disorders. The Company is
presently focused on diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers
that may require amputation and cause disabling chronic pain. The annual cost
of diabetic neuropathies has been estimated at$14 billionintheUnited
States. The company markets the SENSUS™ Pain Management System for treating
chronic pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck^®device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visithttp://www.neurometrix.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.